Immunotherapy for neuroblastoma using mRNA vaccines

Ahmed, Tanvir

doi:10.1016/j.adcanc.2022.100033

Cited by 5 publications

(5 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two Food Drug and Administration (FDA) approved preventive cancer vaccines exist for HPV and HBV-related cancers. Challenges in predicting antigens and achieving substantial immune responses impede the clinical progress of anticancer preventive vaccines ( Ahmed, 2022 ). Top-notch cancer immunotherapy aims to harness the immune system’s potential to eradicate cancer cells efficiently.…”

Section: Immunotherapeutic Approaches To Combat Neuroblastomamentioning

confidence: 99%

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Zheng,

Kumar,

Sharma

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most frequent solid tumor in pediatric cases, contributing to around 15% of childhood cancer-related deaths. The wide-ranging genetic, morphological, and clinical diversity within NB complicates the success of current treatment methods. Acquiring an in-depth understanding of genetic alterations implicated in the development of NB is essential for creating safer and more efficient therapies for this severe condition. Several molecular signatures are being studied as potential targets for developing new treatments for NB patients. In this article, we have examined the molecular factors and genetic irregularities, including those within insulin gene enhancer binding protein 1 (ISL1), dihydropyrimidinase-like 3 (DPYSL3), receptor tyrosine kinase-like orphan receptor 1 (ROR1) and murine double minute 2-tumor protein 53 (MDM2-P53) that play an essential role in the development of NB. A thorough summary of the molecular targeted treatments currently being studied in pre-clinical and clinical trials has been described. Recent studies of immunotherapeutic agents used in NB are also studied in this article. Moreover, we explore potential future directions to discover new targets and treatments to enhance existing therapies and ultimately improve treatment outcomes and survival rates for NB patients.

show abstract

Section: Immunotherapeutic Approaches To Combat Neuroblastomamentioning

confidence: 99%

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Zheng,

Kumar,

Sharma

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The objective of cancer immunotherapy is to manipulate the immune system to effectively eliminate cancer cells [98][99][100]. Immunotherapy mainly targets immune cells.…”

Section: Mrna-based Cancer Immunotherapymentioning

confidence: 99%

“…An overview of therapies is provided in Figure 3. Cancer immunotherapeutics may be divided into four categories: use of recombinant viruses, tumor and immune cell (mainly dendritic cells)-constructed immunizations, and peptide and nucleic acid-based (DNA or RNA) vaccines [41,98] as illustrated in Figure 3. The term "vaccine" is often used instead of immunotherapeutics.…”

Section: Mrna-based Cancer Immunotherapymentioning

confidence: 99%

mRNA—From COVID-19 Treatment to Cancer Immunotherapy

Krause¹

2023

Biomedicines

View full text Add to dashboard Cite

This review provides an overview covering mRNA from its use in the COVID-19 pandemic to cancer immunotherapy, starting from the selection of appropriate antigens, tumor-associated and tumor-specific antigens, neoantigens, the basics of optimizing the mRNA molecule in terms of stability, efficacy, and tolerability, choosing the best formulation and the optimal route of administration, to summarizing current clinical trials of mRNA vaccines in tumor therapy.

show abstract

“…Immunotherapy harnesses the inherent ability of the immune system to combat various diseases. Unlike conventional therapies, immunotherapy works by boosting the body’s immune system’s ability to recognize and eliminate cancerous cells [12, 13]. This approach offers several advantages, including the potential for long-term immunological memory, reduced side effects that are systemic, and the ability to tackle the challenge of tumor heterogeneity.…”

Section: Introductionmentioning

confidence: 99%

WT1 targeting multi-epitope vaccine design for glioblastoma multiforme using immuno-informatics approaches

Ahmed

2024

Preprint

Self Cite

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer classified as grade 4 glioma with a median survival rate of 12-14 months. Currently there is no cure and the conventional treatment outcomes are poor making it imperative to develop novel treatments. WT1, also known as Wilms’ Tumor 1, is a protein that is often found to be overexpressed in GBM and has minimal expression in normal tissues has become a promising target for immunotherapy for its oncogenicity and immunogenicity. This study aimed to develop a multi-epitope vaccine using immuno-informatics approaches that specifically targets the WT1 protein. The WT1 sequence was used to predict B and T cell epitopes which showed probable antigenic, non-allergic and non-toxic properties. Using suitable linker and adjuvants the vaccine construct (370 amino acids) was prepared which were then analyzed for solubility, physicochemical properties, molecular docking to show receptor interactions and molecular dynamics to show stability of the vaccine-receptor complexes. Subsequently, the vaccine sequence was back translated (1110 nucleotides), codon adaptation, pET-28a (+) vector in-silico cloning, and immune response simulations were performed. The designed vaccine lays groundwork for future in-vitro and in-vivo studies and potentially develop it into a novel treatment option for GBM patients.

show abstract

Immunotherapy for neuroblastoma using mRNA vaccines

Cited by 5 publications

References 188 publications

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

mRNA—From COVID-19 Treatment to Cancer Immunotherapy

WT1 targeting multi-epitope vaccine design for glioblastoma multiforme using immuno-informatics approaches

Contact Info

Product

Resources

About